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Uniform risk-adapted treatment protocols and
genetically characterized disease have improved the
outcome of treatment for leukemia and other malig-
nancies. In addition, advances in HLA-typing have
improved outcomes of hematopoietic stem cell trans-
plantation. Despite these efforts to homogenize the
process, outcomes for an individual patient are still
largely unpredictable, with some high-risk patients
doing unexpected well, and some good-risk cases
dying of toxicity of therapy or relapse. In this session
we will explore 3 different aspects of non-HLA poly-
morphism that influence the outcome of treatment.
First, we will discuss genetically determined variations
in the response to drugs—pharmacogenetics—and its
influence on treatment for leukemia and review the
prospects for personalized leukemia therapy. Second,
we will discuss polymorphism in cytokine and other
non-HLA genes that modify outcomes of allogeneic
transplant, irrespective of HLA match. Last, we will
discuss KIR polymorphism, and the opportunities to
harness NK cell cytotoxicity in tumor control.
PHARMACOGENETICS: IDENTIFICATION OF COMMON
GENETIC VARIANTS THAT INFLUENCE RESPONSE TO
DRUGS
Variable response to the dose of the same drug in
different patients is a common clinical experience.
Many different factors may contribute to differential
response including variable age and body size, diet,
gastrointestinal absorption, compliance with therapy,
and characteristics of the drug target, for example,
bacterial resistance to a specific antibiotic. A heritable
component to variable drug response was recognized
in the middle of the 20th century with demonstration
of fast and slow metabolizers of drugs such as debriso-
quine and isoniazid, and of a variable response to the
anti-inflammatory phenylbutazone [1,2]. A significant
genetic component in the metabolism of phenylbuta-
zone was reported in a study published in Science in1201968 [2]. This gloriously simple study used pairs of
volunteer fraternal or monogenic twins, administered
a dose of phenylbutazone and monitored clearance.
The data showed close concordance of pharmacoki-
netic profiles between monogenic twins, and signifi-
cantly more variation between fraternal twins.
Understanding the variable response to drugs
seems particularly pressing in the field of oncology,
in which the stakes are high (failure to cure cancer usu-
ally leads to death), drugs commonly have a narrow
therapeutic index, and toxicities can be severe (a signif-
icant frequency of toxic death is a feature of most AML
protocols, for example). In 1 of the first examples of
pharmacogenetics in oncology, Weinshelboum and
colleagues [3] identified polymorphic responses to
the key antileukemic drug, 6-mercaptopurine (6-MP)
in 1980, and polymorphism of the gene thiopourine
S-methyl transferase (TPMT) remains 1 of the best
understood examples of pharmacogenetic variation.
Candidate Gene Approach to Pharmacogenetics:
The Example of TPMT
TPMT is a cytosolic drug-metabolizing enzyme
that catalyzes the S-methylation of 6-MP and azathio-
prine. In their original seminal study Weinshilboum
and Sladek [3] demonstrated a very clear trimodal fre-
quency of TPMT activity in red blood cells from 298
unrelated control adults. One in 300 subjects lacks
TPMT activity and 11% have intermediate levels.
Family studies showed that the frequency distribution
was because of inheritance. Although phenotypic stud-
ies have shown a clear trimodal distribution, the ge-
netic basis of phenotypic variation has proven more
complex. Seventeen variant TPMT alleles have been
identified to date, although 3 variant alleles account
for the majority (.95%) of persons with intermediate
(1 variant allele) or low (2 variant alleles) TPMT activ-
ity [4,5].
Subsequent clinical studies have demonstrated
very clearly that TPMT polymorphism can predict
toxicity of 6-MP and effectiveness of therapy. Children
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are at higher risk of myelosuppression when prescribed
standard doses of 6-MP [6]. In addition, patients with
low TPMT activity are at increased risk of secondary
cancers [7,8].
Showing a relationship between a polymorphism
at a single locus and outcome of therapy including
multiple drugs that exert cytotoxicty through a number
of different pathways is a challenge. Despite this,
a number of studies have shown that TPMT pheno-
type or genotype influences effectiveness of therapy,
with low TPMT activity being associated with higher
levels of cytotoxic 6-thioguanine nucleotides (6-TGN)
and reduced relapse. Serial clinical studies that have
shown that a combination of measurement of thiopur-
ine metabolites, TPMT status, and clinical tolerance
of therapy can be used to selectively decrease the
dose of 6-MP without decreasing the dose of other
drugs in patients with low or intermediate TPMT
activity, to counsel patients on compliance if levels of
6-TGNs are low, and to increase therapy in patients
with persistently high white blood cell counts. This
careful and rational approach has succeeded in eradi-
cating any adverse effect of TPMT genotype; in the
St. Jude Total XIIIB study the incidence of relapse
was not different in children with a wild-type or inter-
mediate TPMT genotype [9,10].
The generalizability of this labor-intensive and
disciplined approach to other clinical settings, for
example, cooperative groups involving many different
institutions, and treatment regimens that use lower 6-
MP doses than the St. Jude studies (typically 75 mg/
m2/day), remains unclear. The NOPHO ALL-92 pro-
tocol randomized children with B-lineage ALL to have
their 6-MP/methotrexate (MTX) dosage adjusted by
blood counts alone (control group) or by a combina-
tion of blood counts and E-TGN/MTX levels (phar-
macology group) [11]. In the pharmacology group
the doses of 6-MP and/or MTX were adjusted upward
if levels of erythrocyte TGN MTX levels were lower
than a prespecified target. In a surprising result, the
dose adjustment did not improve outcome, and in girls
pharmacologically driven dose adjustment notably
increased the relapse rate. TPMT activity was the
strongest predictor of risk of relapse for girls in the
pharmacology group, and girls who relapsed off ther-
apy had higher TPMT activity than those who did
not relapse, although this was not the case for girls
relapsing on therapy. The reason for these somewhat
counterintuitive outcomes is unclear. The investiga-
tors speculate that attempts to increase the dose of
6-MP lead to increased intracellular levels of methyl-
ated 6-MP metabolites, inhibition of de novo purine
synthesis, and cell cycle arrest of the leukemic blasts.
The investigators conclude that dose adjustment on
the basis of blood counts is sufficient to optimize
outcomes for girls with ALL.Clinical Utilization of Single Gene
Pharmacogenetic Testing
Despite extensive studies performed over 25 years,
the relatively clear-cut clinical significance of this
polymorphism and the commercial availability of
TPMT genotyping in many laboratories in the United
States, TPMT genotyping is not universally used to
regulate therapy. A recent review of current clinical
practice in pharmacogenetic testing in Europe, includ-
ing a relatively small number of practitioners,
indicated that 53% of clinicians who treat with thio-
purine drugs do so without pharmacogenetic testing,
and a further 35% do use the test but not in all patients
who receive treatment [12]. Respondents were asked
about barriers to utilization of TPMT testing, and
notably 25% of respondents thought the clinical utility
of the test to be quite or very low and only 50%
thought utility to be quite high. These data suggest
reluctance to incorporate additional levels of testing
into clinical management, and a level of comfort with
traditional ‘‘trial and error’’ based drug dosing, and
data on improved outcomes will likely need to be com-
pelling to overcome this hesitation in clinical practice.
Moving from Single Gene to Multiple Gene Profiles
Interpretation of pharmacogenetic data increases
in complexity when more than 1 gene, or other nonge-
netic contributors to variable response are considered.
A single drug is commonly used for disorders such as
seizures and hypertension, and such disorders may
lend themselves to pharmacogenetic study analyzing
1, or a small number of genetic variants [13-16]. In
contrast, cancer, and in particular leukemia, is treated
with multiple drugs with multiple different mecha-
nisms of action, and many different genes are involved
in response, each of which has the potential for gene-
gene interactions. Rocha et al [17] genotyped 16 poly-
morphic loci in 246 children with ALL, including 116
children with low risk (LR) and 130 with higher risk
(HR) disease. The data were analyzed used a classifica-
tion and regression tree (CART) analysis and showed
that children in the HR group with the GSTM1
nonnull genotype had an increased risk of relapse.
The risk of relapse was further increased in the pres-
ence of the thymidylate synthetase 3 of 3 genotype,
and both genotypes remained predictive in multivari-
ate analysis. These data are of particular interest be-
cause previous single gene studies, not analyzed
according to leukemia risk group, had failed to identify
any clinical importance of GSTM1 genotype [18,19].
The study of Rocha et al illustrates the complexity of
multiple gene analyses, requiring assessment of multi-
ple genes, sophisticated statistical approaches to
analysis, and stratification of other biologic factors
known to influence outcome, such as National Cancer
Institute (NCI) risk group.
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An alternative to a candidate gene approach is the
application of newer genome-wide approaches (phar-
macogenomics rather than pharmacogenetics) to take
a broad ‘‘discovery-based’’ approach to genes that
may modify response [20,21].
The ability to identify novel genes, not suspected
to be involved in response to a particular drug, is
a very attractive feature of such an approach. It
should be recognized, however, that these approaches
are complementary, with genome-wide studies gener-
ating new candidate genes, each of which then need
to be evaluated individually, and all positive findings
need to be replicated in independent datasets.
Genome-wide approaches include microarray-based
comparisons of gene expression in tissues identified
to be sensitive or resistant to a particular drug or
combination. This approach has been used to
compare gene expression in leukemia cells from chil-
dren resistant or sensitive in vitro to prednisolone,
vincristine, asparaginase, and daunorubicin, and
succeeded in identifying 124 differentially expressed
genes associated with the in vitro phenotype, only 3
of which were previously thought to be important
[22].
Are Pharmacogenetic Data Context Dependent?
Pharmacogenetic findings may be specific to the
therapy protocol in which the observations were
made, limiting the applicability of the findings to
other treatment plans. This is a particular challenge
in oncology when multiple drugs are being used
and the whole ‘‘package’’ needs to be considered,
not just metabolism of a single drug. In an example
of context dependency, we have investigated poly-
morphisms in the metabolic pathway of cytosine ara-
binoside (ara-C), an important component of AML
therapy [23]. Ara-C is irreversibly deaminated by cy-
tidine deaminase (CDD) to a nontoxic metabolite. A
common polymorphism, A79C, in CDD changes a ly-
sine resibecause of glutamine, resulting in decreased
enzyme activity. We determined CDD A79C geno-
types for 457 children with AML treated on proto-
cols CCG 2941 and 2961 and analyzed the impact
of CDD genotype on therapy outcomes. Treat-
ment-related mortality following induction chemo-
therapy was significantly elevated in children with
the CC genotype compared with AA and AC. This
difference was only significant in children random-
ized to receive IDA-FLAG (ara-C 5 7590 mg/m2)
(as consolidation therapy compared to IDA-DCTER
(ara-C 800 mg/m2).
These data demonstrate the likely challenges in
identifying pharmacogenetic profiles that are
generalizable to more than 1 complex therapeutic
protocol.Non-HLA Polymorphism and Outcome of Stem
Cell Transplant
Hematopoietic stem cell transplantation (HSCT)
is the only curative therapy for many hematologic
malignancies, and is currently being used to treat
some cancers and autoimmune diseases. Nevertheless,
the cure rate and 5-year relapse-free survival (RFS) in
adults has remained at 40%-50% for over 2 decades.
This is mainly because of complications posttransplant
including graft-versus-host disease (GVHD) both
acute and chronic (aGVHD, cGVHD), infections
and relapse. Clinical protocols to improve transplant
outcome have included the use of peripheral blood
stem cell transplants (with increasing numbers of
CD341 stem cells), T cell-depletion protocols, and
reduced-intensity conditioning regimens. Even with
these changes in therapeutic protocol and procedure,
the problems to be solved in HSCT include developing
clinical protocols which will: (1) give rise to less GVHD
without a decrease in graft-versus-leukaemia (GVL)
effect; (2) reduce immunosuppression without increas-
ing GVHD; (3) reduce infection rates; (4) reduce inci-
dence of cGVHD, especially in older patients; and (5)
ultimately improve transplant-related mortality
(TRM) and increase survival rates.
Recent research into non-HLA genetics raises the
possibility of clinical trials based on transplant patient
and donor genetic risk assessment that might over-
come some of these problems [24].
Recent research has shown that single nucleotide
polymorphisms (SNPs) and/or microsatellites within
cytokine genes, cytokine receptor genes, and other
non-HLA encoded genes, including those of the innate
immune system may play an important role in deter-
mining HSCT outcome. Different types of SNPs affect
cytokine actions both quantitatively and qualitatively
[25,26]. Microsatellite repeats or SNPs can be found
within the 50 or 30 regulatory sequences (introns) of
genes and alter the structure of transcription factor
binding sites within gene promoters. SNPs can have
a significant effect on gene expression and level of cyto-
kines. Additionally, SNPs can be found within exonic
regions of genes where the sequence variation changes
the coding sequence, changes an amino acid, and there-
fore affects protein structure, or within intronic regions
where the SNPs may affect mRNA splicing and splice
variants. SNPs within untranslated regions can change
mRNA stability and level of protein transcribed. In
addition, for any 1 gene, for example, IL-6, TNF-a,
IL-10, IFN-g, NOD2 /CARD15, multiple SNPs can
exist with close proximity giving rise to linkage disequi-
librium and multiple SNP haplotypes.
Disease-Association Studies
Many SNPs have now been assessed in disease
association studies. The risk of the disease can
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assessed in the context of gene-gene and gene-environ-
ment interactions. The analysis of SNPs may (1) aid in
the understanding of disease pathogenesis and risk, (2)
lead to new therapeutics and or treatment regimes, and
(3) give rise to a better appreciation of the impact of
clinical heterogeneity and effect this has on outcome
in HSCT. Many of the reported cytokine SNPs are
now well documented, and are being studied in both
solid organ transplant settings and autoimmune dis-
ease. In addition, many of these cytokine SNPs have
been associated with high or low levels of cytokine pro-
duction in vitro. Some of these associations, however,
have either not been confirmed or not correlated with
genotypic studies. This may be because of the type of
stimulus used to produce the cytokine in vitro and/or
could be because of linkage disequilibrium of nearby
genes (eg, HSP70 and TNF genes on chromosome
1) may be linked to function [27].
Clinical Studies
Since the first description of the role of cytokine
gene polymorphisms in HSCT in 1998, an increasing
number of studies have confirmed a role of 1 or more
SNPs or microsatellites in predicting HSCT outcome,
including aGVHD and cGVHD, survival, TRM, and
posttransplant infections [28]. The majority of the
studies have been carried out in relatively small and
heterogeneous HLA-matched sibling transplants,
where the potential complication of HLA mismatch-
ing is eliminated. Matched unrelated donor cohorts,
however, have been sparsely studied to date, with few
conclusive results. In addition, relatively few pediatric
cohorts have been tested compared to those of adults.
This research has also recently been reviewed by Dick-
inson and Charron, and Mulligan and Bardy [29-31].
GVHD
The immunopathology of GVHD has been stud-
ied in animal models and early clinical studies. Some
of this work gave rise to a 3-phase model of GVHD
involving a ‘‘cytokine storm, giving rise to tissue dam-
age in target organs of predominantly skin, gut, and
liver. Recent studies have also described the lung tissue
as an important target organ, and the role of different
cell types (antigen presenting cells, T cells, endothelial
cells) and soluble mediators have been described.
During the 3 phases of GVHD either patient or both
patient and recipient genotype may influence out-
come. Phase 1 involves initial tissue damage caused
by total-body irradiation (TBI) and chemotherapy
given during the conditioning regimen pretransplant.
This damage gives rise to activation of host tissues
including dendritic cells, production of cytokines
such as IL-1, TNF-a, IL-6, and IFN-g, together
with associated initiation of the innate immuneresponse. Innate immunity plays an important part in
the initiation of host responses, and involves Toll-
like receptors, and specific receptors for pathogen-
associated molecular patterns (PAMPs) including
genes encoding receptors associated with inflamma-
tory bowel disease. These genes have been associated
with GVHD and TRM in HSCT, that is, the NOD2-
CARD15 genes [32-36]. The influence of these mole-
cules associated with innate immunity and their
receptors may ‘‘set the scene’’ for the ensuing events
of Phase 2 of GVHD, that is, the interaction of the
host with recipient T cells from the incoming graft.
These phases are therefore interdependent, and may
be influenced by the genotype or single nucleotide
polymorphism variant of patient and donor. The final
effector phase involves further host target cell damage
by effector cells of the graft giving rise to increased
cytokine production, activated cytotoxic T cells and
NK cell-dependent pathogens. The pathophysiology
of cGVHD is less well understood, but a number of
polymorphisms with cytokine and other genes have
been associated with cGVHD. The significance and
reason for studying SNPs in HSCT is that they may
be another genetic control mechanism regulating
HSCT complications, and that knowledge of patient
and donor non-HLA genotype could be exploited to
improve transplant outcome by modifying therapeutic
protocols based on individual genetic and clinical risk
assessment.
Genetic polymorphism analysis may therefore
improve outcome prediction over and above standard
clinical prognostic indicators, and this now needs to
be tested in large HSCT cohorts using novel statistical
methodologies to develop a prognostic risk index or
score involving clinical and genetic risk factors. In
the future, individualized GVHD prophylaxis regimes
or conditioning protocols may be possible, based on
donor and recipient genotype at multiple loci.
NK CELLS, KIR POLYMORPHISM, AND OUTCOME OF
TRANSPLANT
NK cells are innate immune effectors capable of
direct lysis of targets and cytokine production, which
are important to fight tumors and viruses. A complex
balance of activating and inhibitory signals transferred
via several classes of receptors, including KIR, regu-
lates NK cell function [37]. Several inhibitory KIRs
recognize ligands that are MHC class I molecules
where ligation protects a target from being killed.
This may explain why NK cells with established lytic
function do not damage normal tissues. The loss of
KIR-ligand expression by an infected or malignant
target renders it susceptible to NK cell lysis. NK cells
can kill tumors without requiring prior sensitization,
can be easily isolated from donor lymphapheresis
products, and do not cause GVHD when infused.
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Human NK cells express KIR, type I transmem-
brane molecules belonging to the Ig superfamily,
which are all are encoded on chromosome 19. KIRs
are named by the number of extracellular immuno-
globulin domains (2D or 3D) and the length of the
intracellular tail that determines whether they are
stimulatory (Short) or inhibitory (Long). A nomencla-
ture committee has assigned a cluster of designation
(CD) number of CD158 for the KIR genes with indi-
vidual loci designated by a small letter6 a number (eg,
KIR3DL1 5 CD158e1) [38]. All individuals contain
the framework genes KIR3DL3, KIR2DL4, and
KIR3DL2. In addition, a variable number of activating
and inhibitory genes are inherited, and population
studies show diverse evolutionary patterns [39]. Indi-
viduals with only 1 activating receptor are referred to
as having an A KIR haplotype. Individuals with more
than 1 activating receptor are referred to as having
a B KIR haplotype. These genes are highly polymor-
phic, and new alleles continue to be reported. Some
of these polymorphisms are functionally important.
For example, KIR3DL1*004 is not expressed on the
surface so it cannot function to recognize its respective
Bw4 ligand [40]. Although the ligands for many KIR
are unknown, the inhibitory receptors KIR2DL1,
KIR2DL2/KIR2DL3, and KIR3DL1 bind HLA class
I C2, C1, and Bw4 alleles, respectively. The KIR
repertoire is determined primarily by KIR genotype
and at steady state is only minimally affected by class
I HLA (KIR-ligand) genes, which segregate indepen-
dently (chromosome 6). The recognition of self-class
I HLA by the higher affinity inhibitory receptors
suppresses NK cell effector responses, including cell-
mediated lysis and cytokine release [41]. In healthy
subjects the KIR repertoire is predicted mainly by
the KIR genotype, although it is influenced by HLA
class I KIR ligand status [42]. The wide allelic variation
in KIR genes includes several common alleles exhibit-
ing poor or no surface expression [40,43-45]. Interest-
ingly, KIR expression is decreased on NK cells
reconstituting in patients after allogeneic HCT in
whom dysregulated KIR expression correlates with
clinical outcomes [46,47].
Allogeneic NK Cell Strategies for Tumor Control
Tumors that express ligands for activating NK
receptors are more responsive to NK cell killing, and
although an attractive strategy, it is difficult to alter
tumor phenotype in vivo. Therefore, more interest
has been focused on ways to manipulate the interac-
tions between inhibitory KIR and their ligands. The
selection of NK cell or stem cell donors based on their
KIR ligand (HLA) status in relation to the patient has
lead to finding higher numbers of alloreactive NK cellsin donors who express a KIR ligand lacking in the
recipient [48].
The 2 main strategies to harness the therapeutic
power of alloreactive NK cells are: (1) stem cell trans-
plantation and (2) adoptive transfer of NK cells. Each
approach has its own advantages and disadvantages.
Advantages to adoptive transfer include minimal toxic-
ity because NK cells are not believed to induce
GVHD. However, the efficacy of adoptive transfer
protocols is limited by the transient nature of the
NK antitumor effect. Alternatively, the beneficial
effects of alloreactive NK cells can be incorporated
into HCT protocols by selecting donors based on 1
of several KIR mismatch algorithms. Although these
strategies assume the risks of HCT (higher treat-
ment-related mortality, GVHD, etc.) they provide
a permanently engrafted potentially alloreactive NK
cell pool that can provide ongoing antitumor activity,
presuming that the alloreactive cells do not become
tolerant after infusion. Although NK cells are the first
lymphocyte population to reconstitute after HCT, the
use of exogenous IL-2 to boost their activity posttrans-
plant is potentially dangerous as it may exacerbate
GVHD. A third option may be to incorporate advan-
tages of both strategies while lessening the cumulative
toxicity associated with 2 separate procedures.
Regardless of the treatment strategy, the first step
is to select a suitable allogeneic donor. The subtleties
between the various methods by which the potential
for KIR alloreactivity between donor and recipient
has been defined have caused confusion. The Perugia
group used the KIR-ligand mismatch or KIR-ligand
incompatibility model, which predicts that donor-
derived NK cells will be alloreactive in the GVH direc-
tion when recipients lack C2, C1, or Bw4 alleles that
are present in the donor [48]. In this model, no allor-
eactivity is predicted for the approximately 1/3 of
recipients who express all 3 KIR ligands. A KIR ligand
match calculator based on this model, which requires
knowledge of both the donor and recipient HLA
types, is available on the Immuno Polymorphism Data-
base (IPD) http://www.ebi.ac.uk/ipd/kir/ligand.html81.
Alternatively, the KIR-ligand absence model catego-
rizes recipients based on their C2, C1, and Bw4 allele
status with no regard to the donor status. As most
human populations have high frequencies of inhibitory
KIR specific for C2, C1, and Bw4 alleles, it is assumed
that most donor-derived NK cells will express inhibi-
tory KIR, and that alloreactive potential is based on
the number of KIR ligands a recipient lacks. The
receptor-ligand model accounts for inhibitory KIR
and recipient KIR ligand status. As KIR genes have
multiple alleles with variable function and expression
levels, this model may be more precise if based not
just on donor KIR genotype but on functional
measures of KIR phenotype. This model allows for
NK alloreactivity in HLA identical transplants where
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expressed on self-tolerant clones in the donor that
may be alloreactive in the posttransplant setting.
Many groups are testing the clinical efficacy of
selecting donors for HCT based on their predicted
alloreactivity against the host using 1 of the models
discussed above. The potential benefits include: (1)
decreased rates of GVHD as host dendritic cells are
killed by donor NK cells [49,50], (2) decreased rates
of graft rejection mediated by NK cell lysis of host T
cells, (3) decreased relapse via direct cytotoxcity [51],
(4) improved engraftment mediated by NK cell release
of hematopoietic cytokines [52,53], and (5) enhanced
immune reconstitution and decreased infectious com-
plications mediated by NK cell antiviral activity. The
Perugia group demonstrated that alloreactive NK
cell clones were detected in patients after stem cell
engraftment in KIR mismatched patients resulting in
improved engraftment, less relapse and less GVHD
[48]. In a recently published update, however, the
only significant effect of KIR mismatch was to reduce
the relapse rates and prolong survival in patients trans-
planted while in complete remission [54]. Results were
less good in patients who were transplanted in relapse.
Additional clinical trials have supported the finding
that KIR ligand mismatch is associated with these
favorable clinical outcomes in myeloid malignancies,
especially when T cells are depleted in vivo with
antithymocyte globulin [55]. However, other studies
looking at outcomes after KIR ligand mismatched T
cell-replete transplants did not find the same effect
[56,57], perhaps because T cells in the graft interfere
with NK cell development and KIR reconstitution
after unrelated donor transplant [58]. Even in the T
cell-deplete setting some investigators have found
the opposite with trials showing worse outcomes in
the KIR mismatched transplants [59]. Analyses based
on KIR ligand absence have also shown conflicting re-
sults. Improved survival has been reported for patients
with myeloid malignancies undergoing HLA-matched
sibling HCT [60] and for patients with myeloid and
lymphoid malignancies after HLA-mismatched unre-
lated HCT [61]. Another study of unrelated HCT
found that KIR ligand absence was associated with de-
creased relapse in early myeloid leukemias, but that pa-
tients with early CML had more GVHD [62]. Taken
together, these results suggest that NK cells play
a role in allogeneic transplant, but the complexities
of the KIR system and the heterogeneity of AML
and other transplanted diseases results in some confu-
sion. There is still hope that results from ongoing trials
aimed at extensive KIR genetic analysis of donor recip-
ient pairs may allow better donor selection to improve
transplant outcome, but this remains to be determined.
Another way to promote antitumor activity with
alloreactive NK cells is through adoptive transfer.
This can be achieved using several strategies. Oneapproach is based on ex vivo NK cell expansion, but
there are several potential limitations. Most impor-
tantly, NK cells stimulated by supraphysiologic con-
centrations of cytokines tend to undergo apoptosis
when removed from ongoing stimulation and may
not persist or expand in vivo. In addition, marked
size changes occur with activation that may alter hom-
ing characteristics in vivo. Consequently, developing
strategies for in vivo NK cell expansion may be opti-
mal. The safety and success of this approach was estab-
lished in a trial using in vivo expanded haploidentical,
related-donor NK cell infusions to treat 43 patients
with metastatic melanoma, metastatic renal cell carci-
noma, refractory Hodgkin disease, and refractory
AML [63]. The trial, which tested 3 preparative che-
motherapy regimens of differing intensity, confirmed
that successful NK cell expansion was only seen in
the AML cohort who received the fully lymphodeplet-
ing cyclophosphamide and fludarabine regimen used
by Rosenberg. Patients received NK cell infusions on
day 0 following 1 or 2 doses of intravenous cyclophos-
phamide (60 mg/kg) days24 and25 and daily intrave-
nous fludarabine (25 mg/m2) days 25 to 21, followed
by 10 million units of subcutaneous IL-2 administered
over 2 weeks. Successful expansion was only seen after
Hi-Cy/Flu, which was the only regimen to induce pan-
cytopenia. Additionally, it was the only 1 to induce
a surge of endogenous IL-15 after chemotherapy. A
significant inverse correlation was seen between the
IL-15 levels and the absolute lymphocyte count, and
high levels correlated with successful NK cell expan-
sion, supporting the importance of IL-15 for NK cell
homeostasis [64].
Eight of 15 evaluable patients had successful in
vivo NK cell expansion, and the circulating donor-
derived NK cells were functional in standard cytotox-
icity assays. Clinical efficacy correlated with in vivo
NK expansion and KIR ligand mismatch. Of the 19 pa-
tients with poor prognosis AML, 5 achieved complete
remissions. The remission patients had significantly
higher proportions of circulating NK cells, which
were significantly more cytotoxic against K562 targets,
suggesting that the observed clinical efficacy was medi-
ated in part by the in vivo-expanded allogeneic donor
NK cells. Furthermore, in this small cohort 4 of the
19 NK donors were predicted to exhibit alloreactivity
based on KIR ligand mismatch in the GVH direction.
CR was achieved in 3 of the 4 (75%) KIR ligand mis-
match and only 2 of 15 (13%) KIR ligand match
patients, supporting a role for KIR ligand mismatching
in the treatment of AML.
Adoptive transfer of allogeneic NK cells is being
studied in several other disease settings based on their
ability to lyse targets in vitro including breast cancer
[65], non-Hodgkin’s lymphoma, multiple myeloma,
hepatocellular carcinoma, melanoma, and renal cell
carcinoma [66-68]. Another approach to achieve the
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adoptive transfer of allogeneic NK cells into standard
HCT protocols. NK cell products are infused either
prior to or during the early recovery phase. Other vari-
ables include cell source and studies are in progress
using haploidentical umbilical cord blood based on
the high frequency of lymphoid precursors found in
that cell source. Other groups are using NK cell donor
lymphocyte infusions (DLI) after haploidentical HCT
to consolidate engraftment in adults with AML [69] or
children with leukemia and solid tumors [70]. Conclu-
sions from these studies await well-designed clinical
trials with definitive clinical and biologic endpoints
to understand the role of NK cells in this process.
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